Clopidogrel Response Variability and Future Therapies: Clopidogrel: Does One Size Fit All?
暂无分享,去创建一个
[1] R. Collins,et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.
[2] V. Pasceri,et al. Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.
[3] R. Carroll,et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization. , 2004, The American journal of cardiology.
[4] M. Packham,et al. Platelet function assays. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.
[5] S. Yusuf,et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.
[6] M. Seyfarth,et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement , 2001, Heart.
[7] D. Clement. A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .
[8] J. Jakubowski,et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. , 2005, Seminars in thrombosis and hemostasis.
[9] C. Macaya,et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. , 2004, European heart journal.
[10] P. Järemo,et al. Individual variations of platelet inhibition after loading doses of clopidogrel , 2002, Journal of internal medicine.
[11] U. Walter,et al. Flow Cytometry Analysis of Intracellular VASP Phosphorylation for the Assessment of Activating and Inhibitory Signal Transduction Pathways in Human Platelets , 1999, Thrombosis and Haemostasis.
[12] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[13] Douglas W Mahoney,et al. Diastolic dysfunction and left atrial volume: a population-based study. , 2005, Journal of the American College of Cardiology.
[14] U. Walter,et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[15] O. Hess,et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. , 2005, Journal of the American College of Cardiology.
[16] L. Wallentin,et al. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. , 2002, Clinical therapeutics.
[17] J. Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.
[18] Paul B. Watkins,et al. Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.
[19] P. Watkins,et al. Contribution of Hepatic Cytochrome P450 3A4 Metabolic Activity to the Phenomenon of Clopidogrel Resistance , 2004, Circulation.
[20] Antonio Colombo,et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. , 2005, European heart journal.
[21] P. Sandset,et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. , 2006, European heart journal.
[22] W. Weaver,et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. , 2006, American heart journal.
[23] P. Morange,et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. , 2006, Journal of the American College of Cardiology.
[24] J. Granada,et al. CLINICAL RESEARCH Interventional Cardiology Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention The Role of Dual Drug Resistance , 2006 .
[25] E. Trabetti,et al. Contribution of Gene Sequence Variations of the Hepatic Cytochrome P450 3A4 Enzyme to Variability in Individual Responsiveness to Clopidogrel , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[26] J. Suh,et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel , 2006, Canadian Medical Association Journal.
[27] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[28] H. McLeod,et al. Clopidogrel pharmacogenetics: promising steps towards patient care? , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[29] A. Kastrati,et al. Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.
[30] H. Hod,et al. Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction , 2004, Circulation.
[31] E. Antman,et al. Clopidogrel resistance: a new chapter in a fast-moving story. , 2004, Circulation.
[32] C. O'connor,et al. Absence of Interaction Between Atorvastatin or Other Statins and Clopidogrel: Results From the Interaction Study , 2004 .
[33] Joseph P Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Journal of the American College of Cardiology.
[34] E. Antman,et al. Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial , 2005, Circulation.
[35] M. Dennis. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .
[36] M. Gawaz,et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.
[37] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[38] Timi Study,et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation , 2005 .
[39] D. Baim,et al. Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.
[40] Deepak L. Bhatt,et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. , 2005, Journal of the American College of Cardiology.
[41] G. Aithal,et al. Warfarin dose requirement and CYP2C9 polymorphisms , 1999, The Lancet.
[42] Lippincott Williams Wilkins,et al. ACC/AHA/SCAI Practice Guidelines, February 21, 2006 , 2006 .
[43] A. Kastrati,et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. , 2004, European heart journal.
[44] A. Siegbahn,et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.
[45] G. Montalescot,et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.
[46] P. Gurbel,et al. Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study , 2005, Circulation.
[47] F. Neumann,et al. Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention , 2005, Circulation.
[48] R. Wilcox,et al. Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes , 2001, Thrombosis and Haemostasis.
[49] Kevin P. Bliden,et al. Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity , 2003, Circulation.
[50] E. Schuetz,et al. Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.
[51] S. Steinhubl,et al. Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial , 2003, Circulation.
[53] U. Walter,et al. CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation , 2003 .
[54] G. Foster. The behavioral approach to treating obesity. , 2006, American heart journal.
[55] P. Gurbel,et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.